Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

Durvalumab and tremelimumab with or without stereotactic body radiation therapy in relapsed small cell lung cancer: a randomized phase II study

Background Immune checkpoint blockade (ICB) targeting programmed cell death protein 1 and cytotoxic T lymphocyte-associated protein 4 has achieved modest clinical activity as salvage therapy in relapsed small cell lung cancer (SCLC). We conducted this signal-finding study to assess the efficacy of I...

Full description

Bibliographic Details
Main Authors: Shuhua Wang, Suresh Ramalingam, Sagar Lonial, Walter Curran, Edmund K Waller, Bassel Nazha, Taofeek K Owonikoko, Conor Steuer, Suchita Pakkala, Kristin Higgins, Zhengjia Chen, Gabriel Sica, Guojing Zhang, Mohammad S Hossain, Tyler Beardslee, Fadlo R Khuri
Format: Article
Language:English
Published: BMJ Publishing Group 2020-07-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/8/2/e001302.full

Internet

https://jitc.bmj.com/content/8/2/e001302.full

Similar Items